Johnson & Johnson (JNJ)

Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.

Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refractory multiple myeloma, while TREMFYA data support an axial psoriatic arthritis label...

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.

Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.